Overview A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age Status: RECRUITING Trial end date: 2025-12-31 Target enrollment: Participant gender: Summary Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.Phase: PHASE1 Details Lead Sponsor: Centessa Pharmaceuticals (UK) Limited